Aduro Biotech (ADRO) Adverse Event was Protocol Violation, Roth Capital Says; Sees Sell-Off as Overreaction

Roth Capital analyst Joseph Pantginis weighed in on Aduro Biotech (NASDAQ: ADRO) after an adverse event in the CRS-207 pancreatic cancer program (listeriosis).

Pantginis commented, "An adverse event in the CRS-207 pancreatic cancer program (listeriosis) is driving negative perception in the stock today, especially after the recent clinical hold being placed on Advaxis' (ADXS-NC). There was a protocol violation and both the patient and the physician requested and were approved to continue receiving therapy. We believe there is an overreaction in ADRO's shares and look to overcome the current negative perception."

The firm maintained a Buy rating and price target of $68.00

For an analyst ratings summary and ratings history on Aduro Biotech click here. For more ratings news on Aduro Biotech click here.

Shares of Aduro Biotech closed at $32.23 yesterday.

You May Also Be Interested In

• Badger Meter (BMI) PT Raised to $175 at Stifel
• Marsh & McLennan (MMC) PT Raised to $221 at Evercore ISI
• Equifax (EFX) PT Raised to $240 at Morgan Stanley